ProfileGDS4814 / ILMN_1730464
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 83% 83% 85% 82% 83% 84% 84% 83% 79% 84% 82% 82% 83% 84% 82% 82% 83% 81% 85% 82% 85% 82% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)195.24783
GSM780708Untreated after 4 days (C2_1)190.37283
GSM780709Untreated after 4 days (C3_1)219.63685
GSM780719Untreated after 4 days (C1_2)168.47182
GSM780720Untreated after 4 days (C2_2)186.24383
GSM780721Untreated after 4 days (C3_2)218.984
GSM780710Trastuzumab treated after 4 days (T1_1)198.94984
GSM780711Trastuzumab treated after 4 days (T2_1)197.29383
GSM780712Trastuzumab treated after 4 days (T3_1)136.32779
GSM780722Trastuzumab treated after 4 days (T1_2)203.19684
GSM780723Trastuzumab treated after 4 days (T2_2)176.70482
GSM780724Trastuzumab treated after 4 days (T3_2)169.83782
GSM780713Pertuzumab treated after 4 days (P1_1)197.18283
GSM780714Pertuzumab treated after 4 days (P2_1)213.79484
GSM780715Pertuzumab treated after 4 days (P3_1)178.22582
GSM780725Pertuzumab treated after 4 days (P1_2)173.48282
GSM780726Pertuzumab treated after 4 days (P2_2)188.51883
GSM780727Pertuzumab treated after 4 days (P3_2)161.51181
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)228.33885
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)172.7382
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)230.57985
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)173.64982
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)178.99482